LY2510924

LY2510924 is a potent and selective CXCR4 antagonist that blocks SDF-1 binding to CXCR4 with an IC50 of 0.079 nM.

Product Specifications

CAS Number

[1088715-84-7]

UNSPSC

12352209

Target

CXCR

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Endocrinology

Assay Protocol

https://www.medchemexpress.com/LY2510924.html

Purity

99.85

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : ≥ 100 mg/mL

Smiles

O=C(NCC(N[C@H](CCC(N[C@H]1CC2=CC=CC=C2)=O)C(N[C@H](C(N)=O)CCCCNC(C)C)=O)=O)[C@@H](NC([C@@](NC([C@@H](NC([C@H](NC1=O)CC3=CC=C(O)C=C3)=O)CCCCNC(C)C)=O)([H])CCCNC(N)=N)=O)CC4=CC(C=CC=C5)=C5C=C4

Molecular Formula

C62H88N14O10

Molecular Weight

1189.45

References & Citations

[1]Peng SB, et al. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models. Mol Cancer Ther. 2015 Feb;14 (2) :480-90.|[2]Cho BS, et al. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood. 2015 Jul 9;126 (2) :222-32.